Faron Pharmaceuticals Oy
LSE:FARN

Watchlist Manager
Faron Pharmaceuticals Oy Logo
Faron Pharmaceuticals Oy
LSE:FARN
Watchlist
Price: 174.5 GBX 1.16% Market Closed
Market Cap: 198.8m GBP

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
€0
/
€0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
GBX0
/
€0

Peer Comparison

Country Company Market Cap Operating
Margin
FI
Faron Pharmaceuticals Oy
LSE:FARN
180.5m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
181.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
157.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Faron Pharmaceuticals Oy
Glance View

Market Cap
198.8m GBX
Industry
Biotechnology

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of treatment for acute organ traumas, vascular damage, and cancer immunotherapy. The company is headquartered in Turku, Lansi-Suomen and currently employs 37 full-time employees. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.

FARN Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top